Group 1 - The company, Jia Shi Tang, reported a revenue of 9.699 billion yuan for the first half of 2025, representing a year-on-year decrease of 24.45% [1] - The net profit attributable to shareholders of the listed company was 107 million yuan, down 36.24% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 96.2624 million yuan, a year-on-year decline of 9.84% [1] - The basic earnings per share were 0.37 yuan [1]

嘉事堂8月29日披露半年报，公司上半年实现营业收入96.99亿元，同比下降24.45%；归属于上市公司股 东的净利润1.07亿元，同比下降36.24%；基本每股收益0.37元。 ...

嘉事堂药业股份有限公司 2025 年半年度报告全文 嘉事堂药业股份有限公司 2025 年半年度报告 2025-32 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 【2025 年 8 月】 1 嘉事堂药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 报告中对公司未来计划的前瞻性陈述不构成公司对投资者的实际承诺， 投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预 测与承诺之间的差异。可能存在行业竞争、经营与管理、市场、国家政策等 风险，敬请广大投资者注意投资风险。 公司负责人徐曦、主管会计工作负责人黄奕斌及会计机构负责人(会计主 管人员)林军声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 以上文件均存放于公司投资证券部/董事会办公室 4 | 目录 | | --- | | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 6 ...

Group 1 - The company focuses on wholesale distribution of pharmaceuticals and medical devices, professional logistics for medical products, and retail pharmacy as its main business areas [1] - The company aims to provide high-quality healthcare products and services to medical institutions, downstream distributors, and end consumers [1] - The current business also includes the sales of innovative drugs [1]

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.33% on August 5, with Jia Shitang leading the gains [1] - The Shanghai Composite Index closed at 3617.6, up 0.96%, while the Shenzhen Component Index closed at 11106.96, up 0.59% [1] Stock Performance Summary - Top gainers included: - Jia Shitang (002462) with a closing price of 15.43, up 5.98% and a trading volume of 207,500 shares, totaling 315 million yuan [1] - Dajia Weikang (301126) at 66.00, up 5.82% with a volume of 349,800 shares, totaling 471 million yuan [1] - Baiyang Pharmaceutical (301015) at 23.11, up 3.22% with a volume of 132,200 shares, totaling 303 million yuan [1] - Other notable performers included: - Renmin Tongtai (600829) at 8.41, up 1.57% [1] - Jiyu Pingmin (301017) at 13.54, up 1.42% [1] Fund Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 170 million yuan from institutional investors, while retail investors contributed a net inflow of 219 million yuan [2] - Notable fund flows included: - Jia Shitang (002462) with a net inflow of 43.79 million yuan from institutional investors, but a net outflow of 37.47 million yuan from retail investors [3] - Dajia Weikang (301126) had a net inflow of 12.46 million yuan from institutional investors, with retail investors showing a net outflow of 10.70 million yuan [3] - Renmin Tongtai (600829) recorded a net inflow of 7.73 million yuan from institutional investors [3]

Core Insights - The core message of the news is that Jiashitang Pharmaceutical Co., Ltd. has successfully obtained dual certification for its compliance management system, marking a significant milestone in its development and demonstrating its commitment to compliance and internal control [2][3]. Group 1: Certification Achievement - Jiashitang has received a compliance management system certification, highlighting its excellence in compliance management and internal control [2]. - The certification reflects Jiashitang's responsibility as a state-owned enterprise and its determination for continuous self-reform [2]. Group 2: Compliance Management Philosophy - The company emphasizes that compliance is the foundation for sustainable development and a source of value creation [2]. - Jiashitang aims to deepen its compliance management system, integrating it with operational management to support business expansion, risk prevention, and brand enhancement [2]. Group 3: Political Responsibility and Industry Self-Regulation - The dual certification is seen as a milestone event that aligns with the central government's regulations and the commitment to strict governance [3]. - Jiashitang demonstrates a strong belief in building a compliance system and maintains a zero-tolerance policy towards violations [3].

Market Overview - The pharmaceutical commercial sector increased by 1.04% on July 30, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 3615.72, up 0.17%, while the Shenzhen Component Index closed at 11203.03, down 0.77% [1] Top Performers - Huaren Health (301408) closed at 15.01, up 5.48% with a trading volume of 334,100 shares and a transaction value of 499 million [1] - Jiazhang Tang (002462) closed at 14.67, up 4.19% with a trading volume of 232,300 shares and a transaction value of 346 million [1] - Laobaixing (603883) closed at 19.69, up 2.93% with a trading volume of 398,800 shares and a transaction value of 779 million [1] - China National Pharmaceutical (600056) closed at 11.28, up 2.64% with a trading volume of 656,900 shares and a transaction value of 747 million [1] Underperformers - Renmin Tongtai (600829) closed at 8.77, down 7.20% with a trading volume of 724,400 shares and a transaction value of 651 million [2] - Saily Medical (603716) closed at 30.89, down 2.31% with a trading volume of 444,300 shares and a transaction value of 1.385 billion [2] - Runda Medical (603108) closed at 18.20, down 1.83% with a trading volume of 299,700 shares and a transaction value of 552 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 62.07 million from institutional investors, while retail investors saw a net inflow of 64.93 million [2] - Major stocks like Laobaixing and China National Pharmaceutical had significant net inflows from retail investors, despite overall sector outflows [3] Individual Stock Analysis - Laobaixing (603883) had a net inflow of 62.57 million from institutional investors, but a net outflow of 45.34 million from retail investors [3] - China National Pharmaceutical (600056) saw a net inflow of 49.86 million from institutional investors, with a net outflow of 43.44 million from retail investors [3] - Huaren Health (301408) had a net inflow of 21.02 million from institutional investors, but a net outflow of 26.49 million from retail investors [3]

Group 1 - Changhua Group received a product purchase contract for carbon-ceramic brake discs, with a total sales amount expected to exceed 100 million yuan over a 5-year lifecycle, starting mass production in Q2 2026 [1] - Zhongke Environmental reported a net profit of 196 million yuan for the first half of 2025, a year-on-year increase of 19.83%, with revenue of 848 million yuan, up 4.48% [1] - WuXi AppTec's net profit for the first half of 2025 grew by 101.92% to 8.561 billion yuan, with revenue of 20.799 billion yuan, a 20.64% increase [1][2] - Sujiao Technology's net profit decreased by 39.54% to 95.39 million yuan, with revenue down 13.75% to 1.776 billion yuan [1] - Jucheng Co. reported a net profit of 205 million yuan, a significant increase of 43.5%, with revenue of 575 million yuan, up 11.69% [1] Group 2 - Sanxiang New Materials plans to invest up to 300 million yuan in a zirconium-hafnium separation project, with a production capacity of 20,000 tons [1] - Koweil received government subsidies totaling 4.9752 million yuan, accounting for 10.14% of its audited net profit [1] - Xinhua Medical obtained two Class II medical device registration certificates for digital X-ray machines [1] - Huanxu Electronics reported a net profit of 638 million yuan, down 18.66%, with total revenue of 27.214 billion yuan, a slight decrease of 0.63% [1] - Zhenhua Co.'s general manager was fined 100,000 yuan for violations related to stock trading by his child [1] Group 3 - Huafeng Aluminum signed a raw material purchase contract worth over 7.2 billion yuan for a five-year period, committing to purchase at least 360,000 tons of raw materials [1] - Hongxin Technology received a project designation letter and procurement contract from a major domestic automotive brand [1] - Meihe Co. obtained a patent for a device used in supporting automatic flipping on conveyor lines in the automotive manufacturing sector [1] - Xin Hongye's subsidiary won a bid for an electrical penetration project worth 40.8831 million yuan [1] - Fuan Pharmaceutical's subsidiary received a drug registration certificate for an injection used in liver disease treatment [1] Group 4 - Tianzhong Precision's subsidiary's bankruptcy liquidation application was accepted by the court due to insufficient assets to cover debts [1] - Zhonghong Medical's subsidiary received medical device registration for infusion pumps and information collection systems [1] - Keda Li's subsidiary completed a capital increase, raising its registered capital from 200 million yuan to 400 million yuan [1] - Xingye Technology applied for a credit limit of 372 million yuan from Guangfa Bank [1] - Hengrui Medicine signed a collaboration agreement with GSK, involving a potential total payment of approximately 12 billion USD based on project milestones [1]

证券代码：002462 证券简称：嘉事堂 公告编号：2025-29 嘉事堂药业股份有限公司 关于取得合规管理体系认证证书的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 三、备查文件 《合规管理体系认证证书》（证书编号：00625CMS20005ROM） 特此公告。 嘉事堂药业股份有限公司董事会 2025 年 7 月 28 日 一、基本情况 嘉事堂药业股份有限公司（以下简称"公司"）近日取得由中质协质量保证 中心颁发的《合规管理体系认证证书》（证书编号：00625CMS20005ROM），兹证 明公司合规管理体系符合 GB/T35770-2022 及 ISO37301:2021 标准。 认证范围：集团总部与药品销售（药品经营许可证范围内）、医疗器械（医 疗器械经营许可证内、医疗器械经营备案凭证内)、医药仓储物流管控有关的合 规管理。 二、对公司的影响 本次获得合规管理体系认证证书，标志着公司合规管理水平已全面接轨国际 标准，证明嘉事堂始终践行"人人讲合规，事事讲合规，时时讲合规，合规创造 价值"的合规理念，持续深耕合规管理体系建设。通过推动 ...

Core Points - The internal audit regulations of Jiasitang Pharmaceutical Co., Ltd. aim to enhance the quality of internal audit work and ensure compliance with relevant laws and regulations [1][2] - The internal audit department is responsible for independent supervision, evaluation, and recommendations regarding the company's operations, financial management, risk management, and internal controls [1][4] Group 1: General Principles - The internal audit work is guided by Xi Jinping's thoughts on socialism with Chinese characteristics and focuses on economic supervision, financial legality, and effectiveness [1][2] - The internal audit department must maintain integrity, objectivity, and independence while avoiding conflicts of interest [2][3] Group 2: Internal Audit Structure - The company has established an internal audit department that reports directly to the board of directors and the audit committee [2][3] - The board of directors is responsible for approving the basic audit system and the annual audit project plan [3][4] Group 3: Responsibilities and Authority - The internal audit department is tasked with auditing the economic responsibilities of management, compliance with national policies, financial management, and internal controls [4][5] - The department has the authority to inspect relevant documents, attend meetings, and report significant issues to the board and the party committee [5][6] Group 4: Audit Types and Procedures - Internal audit activities include economic responsibility audits, routine audits, special audits, and audit research [6][7] - The internal audit department must ensure comprehensive coverage of subsidiaries and adhere to a risk-oriented approach in planning audits [7][8] Group 5: Management and Quality Control - The internal audit department is responsible for managing audit quality and ensuring compliance with established standards [9][10] - The department must not outsource its core functions but may engage third parties for specific audit tasks under supervision [9][10] Group 6: Utilization of Audit Results - The company should establish mechanisms for addressing audit findings and ensuring accountability for corrective actions [10][11] - Audit results are to be used as a reference for evaluating management performance and making personnel decisions [10][11] Group 7: Assessment and Accountability - The company will implement an incentive and accountability mechanism for the internal audit department and its personnel [11][12] - Internal audit personnel may be held accountable for failing to comply with regulations or for misconduct [11][12]